Skip to main content
SpringerLink
Log in

Pharmacologic Treatment of Childhood Hypertension

  • Chapter
  • First Online:
Book cover Pediatric Hypertension

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

Abstract

Hypertension has traditionally been regarded as a rare occurrence in childhood and adolescence; however, there is compelling evidence to suggest that elevated blood pressure is increasingly common in this population. As a result, care providers are increasingly expected to appropriately evaluate and treat hypertensive pediatric patients. This chapter provides an overview of antihypertensive drug therapy in children, including indications for treatment and approaches to optimizing BP control. A detailed review of available antihypertensive agents is provided with an emphasis on pediatric-specific data with respect to dosing, efficacy, and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Loggie J. Letter: detection of hypertension in childhood. Br Med J. 1973;4(5888):356.

    Article  CAS  PubMed  Google Scholar 

  2. Detection of hypertension in childhood. Br Med J. 1973 Sep 15;3(5880):591.

    Google Scholar 

  3. Londe S. Blood pressure standards for normal children as determined under office conditions. Clin Pediatr (Phila). 1968;7(7):400–3.

    Article  CAS  Google Scholar 

  4. Moss AJ, Adams FH. Problems of blood pressure in childhood. Springfield: Charles C. Thomas; 1962.

    Google Scholar 

  5. Roberts J, Maurer K. Blood pressure levels of persons 6-74 years. United States, 1971–1974. Vital Health Stat 11. 1977 Sep;(203):i–v, 1–103.

    Google Scholar 

  6. Blumenthal S, Epps RP, Heavenrich R, Lauer RM, Lieberman E, Mirkin B, et al. Report of the task force on blood pressure control in children. Pediatrics. 1977 May;59(52 suppl):I-II, 797–820.

    Google Scholar 

  7. National high blood pressure education program working group on high blood pressure in children and adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555–76.

    Google Scholar 

  8. Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of “significant” hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr. 1989;114(4 Pt 1):664–9.

    CAS  PubMed  Google Scholar 

  9. Fixler DE, Laird WP, Fitzgerald V, Stead S, Adams R. Hypertension screening in schools: results of the Dallas study. Pediatrics. 1979;63(1):32–6.

    CAS  PubMed  Google Scholar 

  10. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 Pt 1):475–82.

    Article  PubMed  Google Scholar 

  11. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150(6):640e1–44e1.

    Google Scholar 

  12. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488–96.

    Article  PubMed  Google Scholar 

  13. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004;291(17):2107–13.

    Article  CAS  PubMed  Google Scholar 

  14. Boneparth A, Flynn JT. Evaluation and treatment of hypertension in general pediatric practice. Clin Pediatr. 2009;48(1):44–9.

    Article  Google Scholar 

  15. Yoon EY, Cohn L, Rocchini A, Kershaw D, Freed G, Ascione F, et al. Antihypertensive prescribing patterns for adolescents with primary hypertension. Pediatrics. 2012;129(1):e1–8.

    Article  PubMed  Google Scholar 

  16. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719–42.

    Article  CAS  PubMed  Google Scholar 

  17. Hornsby JL, Mongan PF, Taylor AT, Treiber FA. ‘White coat’ hypertension in children. J Fam Pract. 1991;33(6):617–23.

    CAS  PubMed  Google Scholar 

  18. Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics. 2008;122(6):1177–81.

    Article  PubMed  Google Scholar 

  19. Sorof JM, Portman RJ. White coat hypertension in children with elevated casual blood pressure. J Pediatr. 2000;137(4):493–7.

    Article  CAS  PubMed  Google Scholar 

  20. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.

    Article  PubMed  Google Scholar 

  21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.

    Article  CAS  PubMed  Google Scholar 

  22. Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97(19):1907–11.

    Article  CAS  PubMed  Google Scholar 

  23. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics. 2003;111(1):61–6.

    Article  PubMed  Google Scholar 

  24. Hanevold C, Waller J, Daniels S, Portman R, Sorof J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113(2):328–33.

    Article  PubMed  Google Scholar 

  25. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–50.

    Article  PubMed  Google Scholar 

  26. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr. 2006;149(6):746–54.

    Article  CAS  PubMed  Google Scholar 

  27. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20(6):791–7.

    Article  PubMed  Google Scholar 

  28. Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14(6):383–7.

    Article  CAS  Google Scholar 

  29. Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens. 2007;25(12):2370–6.

    Article  CAS  PubMed  Google Scholar 

  30. Prichard BN, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001;10(5–6):366–86.

    CAS  PubMed  Google Scholar 

  31. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60(2):444–50.

    Article  CAS  PubMed  Google Scholar 

  32. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–20.

    Article  CAS  PubMed  Google Scholar 

  33. Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011;33(10):1331–56.

    Article  CAS  PubMed  Google Scholar 

  34. DiBianco R. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure. Postgrad Med. 1985;78(5):229–41. 44, 47–8.

    CAS  PubMed  Google Scholar 

  35. Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17(8):788–9.

    Article  CAS  PubMed  Google Scholar 

  36. Oberfield SE, Case DB, Levine LS, Rapaport R, Rauh W, New MI. Use of the oral angiotensin I–converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr. 1979;95(4):641–4.

    Article  CAS  PubMed  Google Scholar 

  37. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091–100.

    CAS  PubMed  Google Scholar 

  38. United States Food and Drug Administration. Summary of medical and clinical pharmacology reviews. [updated 2008 Jan 15]. Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162982.pdf. Accessed 15 Aug 2012.

  39. Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A. 1986;8(4–5):829–39.

    Article  CAS  PubMed  Google Scholar 

  40. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O’Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103(5):799–805.

    Article  CAS  PubMed  Google Scholar 

  41. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112(5):805–10.

    Article  CAS  PubMed  Google Scholar 

  42. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.

    Article  CAS  PubMed  Google Scholar 

  43. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.

    Article  CAS  PubMed  Google Scholar 

  44. United States Food and Drug Administration. New pediatric labeling information database [updated 2012 July 24]; Available from http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 15 Aug 2012.

  45. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44(3):289–93.

    Article  CAS  PubMed  Google Scholar 

  46. Menon S, Berezny KY, Kilaru R, Benjamin Jr DK, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J. 2006;152(2):394–9.

    Article  CAS  PubMed  Google Scholar 

  47. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614–27.

    Article  PubMed  Google Scholar 

  48. United States Food and Drug Administration. Summaries of medical and clinical pharmacology reviews. Available from www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM161981.pdf. Accessed 15 Aug 2012.

  49. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121(8):656–63.

    Article  CAS  PubMed  Google Scholar 

  50. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183–90.

    Article  CAS  PubMed  Google Scholar 

  51. United States National Institutes of Health. Study of losartan in pediatric patients with hypertension. [updated 2012 June 8]. Available from http://www.clinicaltrials.gov/ct2/show/NCT00756938. Accessed 15 Aug 2012.

  52. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens. 2008;10(10):743–50.

    Article  CAS  Google Scholar 

  53. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083–90.

    Article  CAS  PubMed  Google Scholar 

  54. Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child. 2011;96(9):881–2.

    Article  PubMed  Google Scholar 

  55. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323–30.

    Article  CAS  PubMed  Google Scholar 

  56. Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001;41(7):742–9.

    Article  CAS  PubMed  Google Scholar 

  57. Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15(12):1057–63.

    Article  CAS  PubMed  Google Scholar 

  58. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312–8.

    Article  CAS  PubMed  Google Scholar 

  59. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  CAS  PubMed  Google Scholar 

  60. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  CAS  PubMed  Google Scholar 

  61. Buck ML. Clinical experience with spironolactone in pediatrics. Ann Pharmacother. 2005;39(5):823–8.

    Article  CAS  PubMed  Google Scholar 

  62. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680–91.

    Article  CAS  PubMed  Google Scholar 

  63. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–8.

    Article  PubMed  Google Scholar 

  64. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157(2):282–7.

    Article  CAS  PubMed  Google Scholar 

  65. Kaplan NM, Victor RG. Clinical hypertension. 10th ed. New York: Lippincott Williams and Wilkins; 2010.

    Google Scholar 

  66. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens. 2009;11(7):369–75.

    Article  CAS  Google Scholar 

  67. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150(2):134–9. 9.e1.

    Article  CAS  PubMed  Google Scholar 

  68. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345–50.

    Article  PubMed  Google Scholar 

  69. Robinson RF, Nahata MC, Batisky DL, Mahan JD. Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs. 2005;7(1):27–40.

    Article  PubMed  Google Scholar 

  70. Griswold WR, McNeal R, Mendoza SA, Sellers BB, Higgins S. Propranolol as an antihypertensive agent in children. Arch Dis Child. 1978;53(7):594–6.

    Article  CAS  PubMed  Google Scholar 

  71. Bachmann H. Propranolol versus chlorthalidone–a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta. 1984;39(1):55–61.

    CAS  PubMed  Google Scholar 

  72. Friedman DB, Musch TI, Williams RS, Ordway GA. Beta adrenergic blockade with propranolol and atenolol in the exercising dog: evidence for beta 2 adrenoceptors in the sinoatrial node. Cardiovasc Res. 1987;21(2):124–9.

    Article  CAS  PubMed  Google Scholar 

  73. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269–77.

    Article  CAS  PubMed  Google Scholar 

  74. Dilmen U, Caglar MK, Senses DA, Kinik E. Nifedipine in hypertensive emergencies of children. Am J Dis Child. 1983;137(12):1162–5.

    CAS  PubMed  Google Scholar 

  75. Evans JH, Shaw NJ, Brocklebank JT. Sublingual nifedipine in acute severe hypertension. Arch Dis Child. 1988;63(8):975–7.

    Article  CAS  PubMed  Google Scholar 

  76. Roth B, Herkenrath P, Krebber J, Abu-Chaaban M. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens A. 1986;8(4–5):871–7.

    Article  CAS  PubMed  Google Scholar 

  77. Siegler RL, Brewer ED. Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr. 1988;112(5):811–3.

    Article  CAS  PubMed  Google Scholar 

  78. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276(16):1328–31.

    Article  CAS  PubMed  Google Scholar 

  79. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol. 2002;17(1):35–40.

    Article  PubMed  Google Scholar 

  80. Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr. 2001;139(1):34–7.

    Article  CAS  PubMed  Google Scholar 

  81. Truttmann AC, Zehnder-Schlapbach S, Bianchetti MG. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises. Pediatr Nephrol. 1998;12(3):259.

    CAS  PubMed  Google Scholar 

  82. Flynn JT. Nifedipine in the treatment of hypertension in children. J Pediatr. 2002;140(6):787–8.

    PubMed  Google Scholar 

  83. Silverstein DM, Palmer J, Baluarte HJ, Brass C, Conley SB, Polinsky MS. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant. 1999;3(4):288–92.

    Article  CAS  PubMed  Google Scholar 

  84. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8(6):357–73.

    Article  PubMed  Google Scholar 

  85. Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol. 2002;17(9):748–53.

    Article  PubMed  Google Scholar 

  86. Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J. 2000;93(3):287–93.

    CAS  PubMed  Google Scholar 

  87. Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother. 1997;31(6):704–7.

    CAS  PubMed  Google Scholar 

  88. Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens. 2010;12(11):850–5.

    Article  CAS  Google Scholar 

  89. Blowey DI, Moncica I, Scolnik D, Arbus GS, Hebert D, Balfe JW, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol. 1996;50(1–2):147–8.

    Article  CAS  PubMed  Google Scholar 

  90. Moncica I, Oh PI, ul Qamar I, Scolnik D, Arbus GS, D H. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child. 1995;73(2):154–6.

    Article  CAS  PubMed  Google Scholar 

  91. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18(6):548–53.

    PubMed  Google Scholar 

  92. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304–10.

    Article  CAS  PubMed  Google Scholar 

  93. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens. 2000;13(10):1061–6.

    Article  CAS  PubMed  Google Scholar 

  94. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14(12):1083–7.

    Article  CAS  PubMed  Google Scholar 

  95. von Vigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens. 2001;15(6):387–91.

    Article  CAS  Google Scholar 

  96. Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13(3):198–204.

    Article  PubMed  Google Scholar 

  97. Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol. 2005;20(5):631–5.

    Article  PubMed  Google Scholar 

  98. Flynn JT, Nahata MC, Mahan Jr JD, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905–16.

    Article  CAS  PubMed  Google Scholar 

  99. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145(3):353–9.

    Article  CAS  PubMed  Google Scholar 

  100. Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol. 2003;18(7):675–8.

    PubMed  Google Scholar 

  101. Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc. 1999;39(3):375–7.

    CAS  Google Scholar 

  102. Sinaiko AR, Mirkin BL. Management of severe childhood hypertension with minoxidil: a controlled clinical study. J Pediatr. 1977;91(1):138–42.

    Article  CAS  PubMed  Google Scholar 

  103. Puri HC, Maltz HE, Kaiser BA, Potter DE. Severe hypertension in children with renal disease: treatment with minoxidil. Am J Kidney Dis. 1983;3(1):71–5.

    CAS  PubMed  Google Scholar 

  104. Strife CF, Quinlan M, Waldo FB, Fryer CJ, Jackson EC, Welch TR, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics. 1986;78(5):861–5.

    CAS  PubMed  Google Scholar 

  105. Falkner B, Onesti G, Lowenthal DT, Affrime MB. The use of clonidine monotherapy in adolescent hypertension. Chest. 1983;83(2 Suppl):425–7.

    CAS  PubMed  Google Scholar 

  106. Garovic V, Textor SC. Renovascular hypertension: current concepts. Semin Nephrol. 2005;25(4):261–71.

    Article  PubMed  Google Scholar 

  107. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005;112(9):1362–74.

    Article  PubMed  Google Scholar 

  108. Flynn JT, Pierce CB, Miller 3rd ER, Charleston J, Samuels JA, Kupferman J, et al. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr. 2012;160(3):434e1–40e1.

    Google Scholar 

  109. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–8.

    Article  CAS  PubMed  Google Scholar 

  110. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63(4):1468–74.

    Article  PubMed  Google Scholar 

  111. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996;11(3):461–7.

    Article  CAS  PubMed  Google Scholar 

  112. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939–45.

    Article  CAS  PubMed  Google Scholar 

  113. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997 Jun 28;349(9069):1857–63.

    Google Scholar 

  114. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.

    Article  CAS  PubMed  Google Scholar 

  115. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164–80.

    Article  CAS  PubMed  Google Scholar 

  116. Laragh J. Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14(9 Pt 1):837–54.

    Article  CAS  PubMed  Google Scholar 

  117. Egan BM, Basile JN, Rehman SU, Davis PB, Grob 3rd CH, Riehle JF, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.

    Article  CAS  PubMed  Google Scholar 

  118. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010;23(9):1014–22.

    Article  CAS  PubMed  Google Scholar 

  119. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23(9):1031–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Children’s Hospital Boston Harvard Medical School, Boston, MA, USA

    Michael A. Ferguson M.D.

  2. Division of Nephrology, Seattle Children’s Hospital, Seattle, WA, USA

    Joseph T. Flynn M.D., MS

  3. Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA

    Joseph T. Flynn M.D., MS

Authors
  1. Michael A. Ferguson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph T. Flynn M.D., MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Flynn M.D., MS .

Editor information

Editors and Affiliations

  1. University of Washington, Division of Pediatrics, Seattle Children's Hospital, Sand Point Way NE. 4800, Seattle, 98105, Washington, USA

    Joseph T. Flynn

  2. Harvard Medical School, Pediatric Nephrology Unit, MassGeneral Hospital for Children at MGH, Fruit St. 55, Boston, 02114, Massachusetts, USA

    Julie R. Ingelfinger

  3. Global Clinical Research, Bristol-Myers Squibb, Route 206 & Provinceline Road, Princeton, 08543, New Jersey, USA

    Ronald J. Portman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ferguson, M.A., Flynn, J.T. (2013). Pharmacologic Treatment of Childhood Hypertension. In: Flynn, J., Ingelfinger, J., Portman, R. (eds) Pediatric Hypertension. Clinical Hypertension and Vascular Diseases. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-490-6_36

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-490-6_36

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-489-0

  • Online ISBN: 978-1-62703-490-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation